Post hoc analysis of HELIOS-B in 644 patients with ATTR cardiomyopathy: worse LA reservoir strain predicted death or cardiovascular events (HR 1.37 per 5% worsening), but LA volume did not. Vutrisiran vs placebo lessened LA strain decline at 30 months (+1.2%).
Secondary analysisn = 644
Jering et al. Left Atrial Structure and Function, Clinical Outcomes, and Efficacy of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: A Secondary Analysis of the HELIOS-B Randomized Clinical Trial